Description
PRODUCT DESCRIPTION
Tirzepatide is a synthetic peptide sequence designed to function as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. In specialized research settings, it is widely utilized to investigate dual-pathway metabolic regulation, insulin secretagogue dynamics, and downstream energetic homeostasis.
Structurally, Tirzepatide represents a highly sophisticated approach to metabolic signaling. By concurrently binding to and activating both endogenous GIP and GLP-1 receptors, this compound allows researchers to study the synergistic effects of multi-receptor activation on pancreatic beta-cell response, gastric emptying dynamics, and systemic lipid metabolism models. Unlike isolated single-receptor agonists, this integrated structure provides a more comprehensive framework for mapping complex metabolic pathways.
Our Tirzepatide is synthesized to a 99% purity standard and supplied as a precise 10mg total weight vial. This ensures the absolute chemical stability, zero structural degradation, and baseline consistency required for generating highly reproducible data across all preclinical laboratory applications.
LABORATORY USE DISCLAIMER
This product (Tirzepatide) is sold strictly for research and laboratory purposes only. It is not intended for human consumption, medical diagnosis, therapeutic use, or any form of domestic or veterinary application. The 10mg compound formulation is designed exclusively for evaluated preclinical testing. All potential experimental effects or observations mentioned are derived from controlled in-vitro or animal studies and have not been evaluated or approved by the FDA for human administration. Qualified researchers must handle, store, and utilize this product in strict accordance with standard laboratory safety protocols.
